Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C

253 Pages·2010·1.4 MB·English

by  Colvin

H E PAT I T I S A N D
L I V E R C A N C E R
A National Strategy for Prevention and
Control of Hepatitis B and C
Heather M. Colvin and Abigail E. Mitchell, Editors
Committee on the Prevention and Control of Viral Hepatitis Infections
Board on Population Health and Public Health Practice
THE NATIONAL ACADEMIES PRESS 500 Fifth Street, N.W. Washington, DC 20001
NOTICE: The project that is the subject of this report was approved by the Governing
Board of the National Research Council, whose members are drawn from the councils of
the National Academy of Sciences, the National Academy of Engineering, and the Institute
of Medicine. The members of the committee responsible for the report were chosen for their
special competences and with regard for appropriate balance.
This study was supported by Contract 200-2005-13434, TO#16, between the National Acad-
emy of Sciences and the Department of Health and Human Services (with support from the
Centers for Disease Control and Prevention, the Office of Minority Health, and the Depart-
ment of Veterans Affairs) and by the Task Force for Child Survival and Development on behalf
of the National Viral Hepatitis Roundtable. Any opinions, findings, conclusions, or recommen-
dations expressed in this publication are those of the author(s) and do not necessarily reflect
the view of the organizations or agencies that provided support for this project.
Library of Congress Cataloging-in-Publication Data
Hepatitis and liver cancer : a national strategy for prevention and control of hepatitis B
and C / Heather M. Colvin and Abigail E. Mitchell, editors ; Committee on the Prevention
and Control of Viral Hepatitis Infections, Board on Population Health and Public Health
Practice.
p. ; cm.
Includes bibliographical references and index.
ISBN 978-0-309-14628-9
1. Hepatitis B—United States. 2. Hepatitis C—United States. 3. Liver—Cancer—United
States. I. Colvin, Heather M. II. Mitchell, Abigail E. III. Institute of Medicine (U.S.).
Committee on the Prevention and Control of Viral Hepatitis Infections. IV. Institute of
Medicine (U.S.). Board on Population Health and Public Health Practice. V. National
Academies Press (U.S.)
[DNLM: 1. Hepatitis B—complications—United States. 2. Hepatitis B—prevention &
control—United States. 3. Hepatitis C—complications—United States. 4. Hepatitis C—
prevention & control—United States. 5. Liver Neoplasms—prevention & control—United
States. 6. Viral Hepatitis Vaccines—therapeutic use—United States. WC 536 H5322 2010]
RA644.H4H37 2010
616.99'436—dc22
2010003194
Additional copies of this report are available from the National Academies Press, 500 Fifth
Street, N.W., Lockbox 285, Washington, DC 20055; [phone] or [phone] (in
the Washington metropolitan area); Internet, http://www.nap.edu.
For more information about the Institute of Medicine, visit the IOM home page at www.
iom.edu.
Copyright 2010 by the National Academy of Sciences. All rights reserved.
Printed in the United States of America
The serpent has been a symbol of long life, healing, and knowledge among almost all cultures
and religions since the beginning of recorded history. The serpent adopted as a logotype by
the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche
Museen in Berlin.
Suggested citation: IOM (Institute of Medicine). 2010. Hepatitis and Liver Cancer: A National
Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National
Academies Press.
“Knowing is not enough; we must apply.
Willing is not enough; we must do.”
—Goethe
Advising the Nation. Improving Health.
The National Academy of Sciences is a private, nonprofit, self-perpetuating society
of distinguished scholars engaged in scientific and engineering research, dedicated to
the furtherance of science and technology and to their use for the general welfare.
Upon the authority of the charter granted to it by the Congress in 1863, the Acad-
emy has a mandate that requires it to advise the federal government on scientific
and technical matters. Dr. Ralph J. Cicerone is president of the National Academy
of Sciences.
The National Academy of Engineering was established in 1964, under the charter
of the National Academy of Sciences, as a parallel organization of outstanding en-
gineers. It is autonomous in its administration and in the selection of its members,
sharing with the National Academy of Sciences the responsibility for advising the
federal government. The National Academy of Engineering also sponsors engineer-
ing programs aimed at meeting national needs, encourages education and research,
and recognizes the superior achievements of engineers. Dr. Charles M. Vest is presi-
dent of the National Academy of Engineering.
The Institute of Medicine was established in 1970 by the National Academy of
Sciences to secure the services of eminent members of appropriate professions in
the examination of policy matters pertaining to the health of the public. The Insti-
tute acts under the responsibility given to the National Academy of Sciences by its
congressional charter to be an adviser to the federal government and, upon its own
initiative, to identify issues of medical care, research, and education. Dr. Harvey V.
Fineberg is president of the Institute of Medicine.
The National Research Council was organized by the National Academy of Sci-
ences in 1916 to associate the broad community of science and technology with the
Academy’s purposes of furthering knowledge and advising the federal government.
Functioning in accordance with general policies determined by the Academy, the
Council has become the principal operating agency of both the National Academy
of Sciences and the National Academy of Engineering in providing services to the
government, the public, and the scientific and engineering communities. The Coun-
cil is administered jointly by both Academies and the Institute of Medicine. Dr.
Ralph J. Cicerone and Dr. Charles M. Vest are chair and vice chair, respectively, of
the National Research Council.
www.national-academies.org
COMMITTEE ON THE PREvENTION AND
CONTROL OF vIRAL HEPATITIS INFECTIONS
R. Palmer Beasley (Chair), Ashbel Smith Professor and Dean Emeritus,
University of Texas, School of Public Health, Houston, Texas
Harvey J. Alter, Chief, Infectious Diseases Section, Department of
Transfusion Medicine, National Institutes of Health, Bethesda, Maryland
Margaret L. Brandeau, Professor, Department of Management Science
and Engineering, Stanford University, Stanford, California
Daniel R. Church, Epidemiologist and Adult Viral Hepatitis Coordinator,
Bureau of Infectious Disease Prevention, Response, and Services,
Massachusetts Department of Health, Jamaica Plain, Massachusetts
Alison A. Evans, Assistant Professor, Department of Epidemiology
and Biostatistics, Drexel University School of Public Health,
Drexel Institute of Biotechnology and Viral Research, Doylestown,
Pennsylvania
Holly Hagan, Senior Research Scientist, College of Nursing, New York
University, New York
Sandral Hullett, CEO and Medical Director, Cooper Green Hospital,
Birmingham, Alabama
Stacene R. Maroushek, Staff Pediatrician, Department of Pediatrics,
Hennepin County Medical Center, Minneapolis, Minnesota
Randall R. Mayer, Chief, Bureau of HIV, STD, and Hepatitis, Iowa
Department of Public Health, Des Moines, Iowa
Brian J. McMahon, Medical Director, Liver Disease and Hepatitis
Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska
Martín Jose Sepúlveda, Vice President, Integrated Health Services,
International Business Machines Corporation, Somers, New York
Samuel So, Lui Hac Minh Professor, Asian Liver Center, Stanford
University School of Medicine, Stanford, California
David L. Thomas, Chief, Division of Infectious Diseases, Department of
Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
Lester N. Wright, Deputy Commissioner and Chief Medical Officer, New
York Department of Correctional Services, Albany, New York
Study Staff
Abigail E. Mitchell, Study Director
Heather M. Colvin, Program Officer
Kathleen M. McGraw, Senior Program Assistant
Norman Grossblatt, Senior Editor
Rose Marie Martinez, Director, Board on Population Health and Public
Health Practice
v

Reviewers
This report has been reviewed in draft form by persons chosen for
their diverse perspectives and technical expertise, in accordance with
procedures approved by the National Research Council’s (NRC’s)
Report Review Committee. The purpose of this independent review is to
provide candid and critical comments that will assist the institution in mak-
ing its published report as sound as possible and to ensure that the report
meets institutional standards for objectivity, evidence, and responsiveness
to the study charge. The review comments and draft manuscript remain
confidential to protect the integrity of the deliberative process. We wish to
thank the following individuals for their review of this report:
Scott Allen, Brown University Medical School
Jeffrey Caballero, Association of Asian Pacific Community Health
Organizations
Colleen Flanigan, New York State Department of Health
James Jerry Gibson, South Carolina Department of Health and
Environmental Control
Fernando A. Guerra, San Antonio Metropolitan Health District
Theodore Hammett, Abt Associates Inc.
Jay Hoofnagle, National Institute of Diabetes and Digestive and
Kidney Diseases
Charles D. Howell, University of Maryland School of Medicine
Walter A. Orenstein, Bill & Melinda Gates Foundation
Philip E. Reichert, Florida Department of Health
Charles M. Rice III, The Rockefeller University
vii
viii REVIEWERS
Tracy Swan, Treatment Action Group
Su Wang, Charles B. Wang Community Health Center
John B. Wong, Tufts Medical Center
Although the reviewers listed above have provided many constructive
comments and suggestions, they were not asked to endorse the conclusions
or recommendations, nor did they see the final draft of the report before
its release. The review of the report was overseen by Bradford H. Gray,
Senior Fellow, The Urban Institute, and Elena O. Nightingale, Scholar-in-
Residence, Institute of Medicine. Appointed by the Institute of Medicine
and the National Research Council, they were responsible for making cer-
tain that an independent examination of the report was carried out in ac-
cordance with institutional procedures and that all review comments were
carefully considered. Responsibility for the final content of the report rests
entirely with the author committee and the institution.
Acknowledgments
The committee acknowledges the valuable contributions made by the
many persons who shared their experience and knowledge with the
committee. The committee appreciates the time and insight of the pre-
senters during the public sessions: John Ward, Dale Hu, Cindy Weinbaum,
and David Bell, Centers for Disease Control and Prevention; Chris Taylor
and Martha Saly, National Viral Hepatitis Roundtable; Lorren Sandt, Car-
ing Ambassadors Program; Joan Block, Hepatitis B Foundation; Gary
Heseltine, Council of State and Territorial Epidemiologists; William Rogers,
Centers for Medicare and Medicaid Services; Tanya Pagán Raggio Ashley,
Health Resources Services Administration; Carol Craig, National Associa-
tion of Community Health Centers; Daniel Raymond, Harm Reduction
Coalition; and Mark Kane, formerly of the Children’s Vaccine Program,
PATH. We are also grateful for the thoughtful written and verbal testimony
provided by members of the public affected by hepatitis B or hepatitis C.
Several persons contributed their expertise for this report. The com-
mittee thanks David Hutton, of the Department of Management Science
and Engineering at Stanford University; victor Toy, Beverly David, and
Kathleen Tarleton, of IBM; Shiela Strauss, of the New York University
College of Nursing; Ellen Chang and Stephanie Chao, of the Asian Liver
Center at Stanford University; Gillian Haney, of the Massachusetts Depart-
ment of Public Health; and all the State Adult Viral Hepatitis Prevention
Coordinators that provided information to the committee.
This report would not have been possible without the diligent assistance
of Jeffrey Efird and Daniel Riedford, of the Centers for Disease Control and
ix